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Cigarette smoking is associated 
with an altered vaginal tract 
metabolomic profile
T. M. Nelson  1,2, J. C. Borgogna1,2, R. D. Michalek3, D. W. Roberts4, J. M. Rath5,6, E. D. 
Glover5, J. Ravel  7,8, M. D. Shardell9, C. J. Yeoman1,2 & R. M. Brotman  7,10
Cigarette smoking has been associated with both the diagnosis of bacterial vaginosis (BV) and a 
vaginal microbiota lacking protective Lactobacillus spp. As the mechanism linking smoking with 
vaginal microbiota and BV is unclear, we sought to compare the vaginal metabolomes of smokers 
and non-smokers (17 smokers/19 non-smokers). Metabolomic profiles were determined by gas and 
liquid chromatography mass spectrometry in a cross-sectional study. Analysis of the 16S rRNA gene 
populations revealed samples clustered into three community state types (CSTs) ---- CST-I (L. crispatus-
dominated), CST-III (L. iners-dominated) or CST-IV (low-Lactobacillus). We identified 607 metabolites, 
including 12 that differed significantly (q-value < 0.05) between smokers and non-smokers. Nicotine, 
and the breakdown metabolites cotinine and hydroxycotinine were substantially higher in smokers, 
as expected. Among women categorized to CST-IV, biogenic amines, including agmatine, cadaverine, 
putrescine, tryptamine and tyramine were substantially higher in smokers, while dipeptides were 
lower in smokers. These biogenic amines are known to affect the virulence of infective pathogens and 
contribute to vaginal malodor. Our data suggest that cigarette smoking is associated with differences 
in important vaginal metabolites, and women who smoke, and particularly women who are also 
depauperate for Lactobacillus spp., may have increased susceptibilities to urogenital infections and 
increased malodor.
According to the U.S. National Health Interview Survey, 13.9 percent of U.S. women reported that they smoked 
cigarettes in 20161, and it has been well-documented that women who smoke have greater risks for adverse repro-
ductive health outcomes, including premature birth, delivery of low birth weight infants, certain birth defects, and 
ectopic pregnancy2–6. Smokers are also more susceptible to bacterial infections than non-smokers7, however, few 
studies have investigated the mechanisms linking smoking and gynecologic infections. Smoking has been shown 
in large observational studies to be a dose-dependent risk factor for the diagnosis of bacterial vaginosis (BV)8–13, 
as well as significantly associated with risk of other genital infections in females including Trichomonas vaginalis14, 
herpes simplex virus type 2 (HSV-2)15 and Chlamydia trachomatis16,17. Smoking has long been implicated in 
higher risk for oral and genital human papillomavirus (HPV) prevalence and viral load, progression to cervical 
pre-cancer, and vulval intraepithelial neoplasia18–23. Smoking is associated with damaged cervical epithelium 
through DNA modification and suppressed local and systemic immune responses24, both of which may increase 
susceptibility to a wide range of female reproductive tract infections25,26. Nicotine’s major metabolite, cotinine, 
has been shown to become concentrated in cervical mucus, providing evidence that smoking can directly affect 
the vaginal and cervical epithelium27,28. Smoking cessation was also associated with dramatic changes in the gut 
microbiota in one study29.
1Department of Animal and Range Sciences, Montana State University, Bozeman, MT, USA. 2Department of 
Microbiology and Immunology, Montana State University, Bozeman, MT, USA. 3Metabolon Inc, Durham, NC, USA. 
4Department of Ecology, Montana State University, Bozeman, MT, USA. 5Department of Behavioral and Community 
Health, University of Maryland School of Public Health, College Park, MD, USA. 6Truth Initiative, Washington DC, 
USA. 7Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. 8Department 
of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. 9Translational 
Gerontology Branch, National Institute on Aging, Baltimore, MD, USA. 10Department of Epidemiology and Public 
Health, University of Maryland School of Medicine, Baltimore, MD, USA. Correspondence and requests for materials 
should be addressed to C.J.Y. (email: carl.yeoman@montana.edu) or R.M.B. (email: rbrotman@som.umaryland.edu)
Received: 13 July 2017
Accepted: 18 October 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC RePoRTS |  (2018) 8:852  | DOI:10.1038/s41598-017-14943-3
In a 2014 study, our research group confirmed that the composition of the vaginal microbiota is strongly 
associated with smoking30. In that study, we compared the vaginal microbiota, as determined by 16S rRNA 
gene amplicon sequencing, between smokers and non-smokers. We reported that women who had a vaginal 
microbiota that were lacking significant numbers of Lactobacillus spp. were 25-fold more likely to report current 
smoking than women with a L. crispatus-dominated microbiota. Most Lactobacillus spp. are thought to provide 
broad-spectrum protection to pathogenic infections through the production of lactic acid and bacteriocins31,32. 
The lactic acid reduces the vaginal pH to ≤4.0 and is a potent bactericide and virucide31,33–36. Indeed, epidemio-
logic studies have shown that a relatively low level of Lactobacillus spp. and the presence of a wide array of strict 
and facultative anaerobes in the vaginal microbiota, as observed in the clinical diagnosis of BV, is associated with 
increased incidence of HIV and other sexually transmitted infections (STIs)15,37–43.
Despite advances in understanding the epidemiologic links between smoking and women’s reproductive 
health, the mechanistic processes by which smoking affects the vaginal microenvironment and BV is unclear. 
The effect of smoking on the function of the microbiome can be investigated by assessing the metabolome. The 
metabolome is the set of small (<1 kDa) molecule chemicals, which includes host and microbially-produced and 
modified biomolecules, as well as exogenous chemicals44. Measurement of the metabolomic profile from any 
biological sample is expected to contain numerous low molecular mass molecules with different physicochemical 
characteristics and concentration ranges44.
The metabolome is an important characteristic of the vaginal microenvironment and differences in some 
metabolites are associated with functional variations of the vaginal microbiota45–48. For example, the presence 
of certain chemicals or metabolites have been shown in vitro to directly reduce or inhibit the growth of select 
bacterial species49–51. Biosynthesis of biogenic amines (BAs) (cadaverine, putrescine, spermine, spermidine, tri-
methylamine, and tyramine) may allow various bacteria to survive in low pH environments52, like that found in 
the healthy Lactobacillus-dominated vagina. BAs have also been shown to enhance growth rates of various path-
ogenic bacteria, such as Neisseria gonorrhoeae, and shield them from host innate immunological defenses53–55. 
The recent applications of metabolomics with in vivo samples have identified relationships between bacterial 
species and vaginal metabolomic profiles. In particular Dialister, Mobiluncus, Atopobium, Prevotella, Mycoplasma 
and Gardnerella species were correlated with the presence of several metabolites along with vaginal odor and 
discharge45–48. We have hypothesized that BAs may be an important feature in the destabilization of Lactobacillus 
spp.-dominant vaginal microbiota and the initiation of BV, as well as the characteristic malodor of BV56. The 
decarboxylation of amino acid precursors to form BAs results in increased pH and may increase the risk for BV57.
In this study, we sought to characterize vaginal microbiota functional differences between smokers and 
non-smokers by investigating the vaginal metabolome. These data may allow enhanced understanding of the 
mechanism by which smoking may increase the risk of urogenital infections and may contribute to our under-
standing of the effect of smoking on the female reproductive tract.
Results
In total, 607 compounds were identified in the vaginal metabolome of 36 women. PCA indicated that the metab-
olomic profiles clustered by both smoking status and bacterial community state type (CST) (Figure S1). CST 
accounted for 23% of the metabolite variation observed in the complete data set (distance based linear model, 
DISTLM F = 9.9397, PPERM = 0.0001; Table 1), while smoking status explained 6%. However, the concentrations 
of 12 metabolites were significantly different between smokers and non-smokers (q-value = <0.05; Fig. 1A, 
Table S1). Tobacco constituents and their primary breakdown products (nicotine, cotinine and hydroxycotinine) 
represented the strongest differences between smokers and non-smokers with non-smokers having a 2- to 12-fold 
reduction in these compounds (q-value = <0.05). After adjusting for the influence of CST, five of the metabolites 
persisted in their differences between smokers and non-smokers (Figs 1B, 2).
Further, 142 metabolites had abundances that were marginally significantly different between smokers and 
non-smokers (q-value between 0.05 and 0.10) without adjustment for CST (Table S2). These compounds are 
Variable SS (trace) Pseudo-F p-value Proportion (%)
Cumulative 
Proportion (%)
Individual model test
CST 3181.00 9.94 0.002 22.62 NA
Smoking status 880.65 2.27 0.074 6.26 NA
Race 1120.00 2.94 0.033 7.96 NA
Education level 1216.90 3.22 0.038 8.65 NA
Fitted model with selected variables, adjusted R2 = 0.26
CST 3181.00 9.94 0.001 22.62 22.62
Race 817.71 2.68 0.037 5.82 28.44
Education level 533.18 1.79 0.11 3.79 32.23
Smoking status 292.20 0.98 0.37 2.08 34.31
Table 1. Significantly fitted predicator variables to vaginal metabolites. Distance based linear modelling 
(DISTLM) was performed on vaginal metabolites fitted with participant behavioral variables listed in Table 2. 
DISTLM was conducted with adjusted R2 over 9,999 permutations. DISTLM identifies the best-fit model based 
on all the available variables that best-explain the composition of vaginal metabolites. The visual display of these 
data as represented by the distance-based redundancy analysis (dbRDA) plot is displayed in Fig. 3.
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involved in amino acid metabolism, including some essential for bodily functions such as lysine, tryptophan, 
leucine, isoleucine, histidine and methionine as well as many amino acid dipeptides required for protein hydrol-
ysis. Interestingly, the greatest differences in the composition and abundance of the metabolomes between 
smokers and non-smokers were among biogenic amines, including, cadaverine (fold change in non-smokers, 
FC = −53.19), putrescine (FC = −15.80), agmatine (FC = −15.49), tyramine (FC = −5.15) and tryptamine 
(FC = −4.43), which were much higher in smokers (Table S2, Figure S2).
Figure 1. Compounds differing between smokers and non-smokers with and without adjustment for CST. 
Volcano plots display –log10 (p-value) and the median difference in concentration between smokers and non-
smokers when unadjusted (A) and adjusted for community state type (B). Quantile regression was conducted 
on centered and scaled metabolite concentrations. Significance testing was conducted with Wilcoxon rank 
sum test and corrected for multiple comparisons. Metabolites that differed significantly where q-value < = 0.05 
between smokers and non-smokers are shown above the line in each plot.
Figure 2. Vaginal metabolites that differ between smokers and non-smokers. Boxplots display metabolites 
identified as significantly (q-value = <0.05) different in the vagina of smokers and non-smokers when 
unadjusted and adjusted for the impact of bacterial community state type (CST). Samples categorized as CST-I 
(L. crispatus-dominated) and CST-III (L. iners-dominated) were grouped and compared with CST-IV (low-
Lactobacillus spp.). Quantile regression was conducted on centered and scaled metabolite concentrations. 
Significance testing was conducted with Wilcoxon rank sum test and corrected for multiple comparisons.
www.nature.com/scientificreports/
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Non-smoker Smoker
p-value1n % n %
Participant details
Age 0.011
  19–28 16 44 4 11
  29–38 1 3 6 17
  39–48 2 6 7 19
Marital status 0.066
  Single, never married 17 47 8 22
  Separated, divorce, widowed 1 3 5 14
  Married 1 3 3 8
Race 0.170
  Asian/Pacific Islander 3 8 1 3
  White 8 22 4 11
  African American/black 4 11 10 28
  Hispanic 3 8 0 0
  Multi-racial 1 3 1 3
  Other 0 0 1 3
Education level 1.000
  High School, up to 12 years 0 0 1 3
  College and graduate, > 12 years 19 53 16 44
Clinical
CST 0.011
  I, L. crispatus-dominated 13 36 4 11
  III, L. iners-dominated 4 11 3 8
  IV, Low-Lactobacillus spp. 2 6 10 28
Nugent’s Gram stain score 0.000
  0–3 17 47 8 22
  4–6 2 6 2 6
  7–9 0 0 7 19
Vaginal pH 0.004
  <=4.0 10 28 4 11
  4.1–5.5 1 5 1 3
  4.6–5.0 4 11 2 6
  >=5.1 4 11 10 28
Self-reported symptoms
Vaginal odor 0.969
  No 15 42 16 44
  Yes 4 11 1 3
Vaginal irritation, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Vaginal itching, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Vaginal burning, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Pain urinating, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Vaginal discharge, 24 hours prior 0.847
  No 14 39 14 39
  Yes 5 14 3 8
Continued
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Non-smoker Smoker
p-value1n % n %
Participant details
Hygiene
Vaginal douche, 2 months prior 0.108
  No 18 50 9 25
  Yes 1 3 7 19
  Not recorded 0 0 1 3
Menstruating currently 0.075
  No 9 25 9 25
  Yes 10 28 8 22
Tampon or pad, 24 hours prior 0.456
  No pad, no tampon 10 28 10 28
  Pad only 2 6 1 3
  Tampon only 4 11 2 6
  Tampon and pad 2 6 1 3
  Not recorded 1 3 3 8
Sexual behaviors
Lifetime number of sexual partners 0.25
  0–6 13 36 3 8
  7+ 6 17 12 33
  Not recorded 0 0 2 6
Number of sex partners, 2 months prior 0.000
  0 4 11 2 6
  1 12 33 14 39
  2 3 8 1 3
Vaginal intercourse with a condom, 24 
hours prior 0.673
  No vaginal intercourse 14 39 9 25
  Vaginal intercourse no condom 3 8 6 17
  Vaginal intercourse with condom 2 6 2 6
Anal intercourse, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Sex toy use, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Lubricant use, 24 hours prior 1.000
  No 19 53 17 47
  Yes 0 0 0 0
Partner type 0.000
  Regular 10 28 12 33
  Occasional 2 6 0 0
  New 1 3 0 0
  Not recorded 6 17 5 14
Receptive oral sex, 24 hours prior 0.543
  Yes 2 6 1 3
  No 17 47 16 44
Digital penetration, 24 hours prior 0.555
  Yes 3 8 2 6
  No 16 44 15 42
Thong use, 24 hours prior 0.000
  Yes 6 17 3 8
  No 13 36 13 36
  Not recorded 0 0 1 3
Table 2. Factors associated with smoking status, Baltimore, MD (n=36) 1p-value determined using Fisher’s 
exact test.
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The associations observed between smoking and the vaginal metabolome may be explained in part by 
participant-specific variables, such as sexual behaviors, health, race and other confounding factors. We utilized 
a distance-based linear modeling (DISTLM) approach to explain the contribution of confounding participant 
variables to the vaginal metabolome (Table 1). Due to the relatively small sample size of our study, the model was 
limited to a total of four variables, which we selected as the best fit from all potential models with the inclusion 
of smoking status and CST. The model including CST, race, education level, and smoking status, had an adjust-
edR2 of 0.26, and these variables explained 34% of the observed variation in the vaginal metabolomic profiles 
(Table 1). Using this analytical approach based on the full metabolome, smoking status did not show a statistically 
significant relationship to the full spectrum of vaginal metabolites after adjustment for CST, race, and education, 
although in some cases, when the associations are large and the p-values do not reach significance, it may be due 
to the lack of power associated with the relatively small sample size (Fig. 3, Table 1).
In addition to the multivariate analyses above, we also sought to directly contrast the metabolome of 
Lactobacillus-dominated CST-I/III and the low-Lactobacillus/diverse anaerobes observed in CST-IV. To increase 
the power of significance testing, we combined L. crispatus-dominated CST-I and L. iners-dominated CST-III. In 
bivariate analysis, there was a significant difference (q-value < = 0.05) in the concentrations of 67% of all identi-
fied vaginal metabolites between CST-I/III and CST-IV (Table S3). After adjusting for the influence of a woman 
being a current smoker, the abundance of 54% of vaginal metabolites still differed significantly (q-value < = 0.05). 
The majority of the metabolites that were elevated in the Lactobacillus-dominated CSTs were amino acids, lipids, 
peptides and especially dipeptides (Fig. 4). Carbohydrates, mannitol, lactate, xylulose and fucose were higher in 
the Lactobacillus-dominated CSTs compared to CST-IV (Table S3). The glycine conjugate of benzoic acid, hippu-
rate, was also markedly higher (34-fold) in Lactobacillus-dominated communities. The BAs (cadaverine, putres-
cine, agmatine, tyramine, tryptamine) and the straight chain fatty acid deoxycarnitine were also observed to be 
significantly higher in CST-IV compared to Lactobacillus-dominant communities (Table S3). Correlations with 
pH measurement and BA concentrations were positive, yet lacked statistical significance (Table S4, Figure S3).
Further, among women in CST-IV, the BAs were markedly higher in smokers versus non-smokers (q-value: 
<0.05, Cadaverine (89-fold), Putrescine (26-fold), Agamatine (26-fold), Tyramine (10-fold) and Trypatamine 
(7-fold), Figure S2).
Discussion
Our group and others have previously reported that female smokers are more likely to display a low-Lactobacillus 
CST-IV vaginal microbiota and are at increased risk for morbidities such as bacterial vaginosis9,30 and sexually 
transmitted infections39. To obtain greater insight into this relationship, we assessed the vaginal metabolome of 
smokers and non-smokers. Using a comprehensive metabolomics approach and multiple analyses of the data, 
we identified an extensive and diverse range of vaginal metabolites for which profiles were affected by both the 
microbiology and smoking status. Bacterial composition (CST) was the most pronounced driver of the vaginal 
metabolome in our model and was associated with changes in 57% of all metabolites, suggesting vaginal micro-
biota are the major drivers of the vaginal metabolome. We therefore carefully controlled for CST in multivariate 
Figure 3. Participant predictor variables fitted to vaginal metabolites. Distance-based linear modelling 
(DISTLM) was conducted on log-transformed Euclidean distance matrix of vaginal metabolites. All variables 
were included in the final model that when applied to the data cloud of vaginal metabolites (Table 1). Distance-
based redundancy analysis (dbRDA) plot (A) displays the metabolite composition fitted to the four variables 
labeled with the strongest variable, CST. Variable vectors indicating strength and direction are identified (B).
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analysis and also conducted stratified analysis based on CST so that we could directly contrast smokers versus 
non-smokers, while essentially holding CST constant. As expected, nicotine and its breakdown products were 
markedly elevated in the vagina of smokers. In humans, 70–80% of nicotine is converted to cotinine followed by 
conversion to hydroxycotinine58. Hydroxycotinine is a well-known biomarker identified in the urine, plasma and 
serum of individuals exposed to both active and passive smoking59–61. Previous studies have identified nicotine 
and cotinine in the cervical mucus of smokers27 with good correlation to concentrations in blood and urine62,63. 
Our findings are consistent with the vaginal metabolome contributing to the mechanism linking smoking to the 
microbiome.
Another key finding was that we observed significant increases in the abundance of various BAs among smok-
ers relative to non-smokers, which was far more pronounced in women with a low-Lactobacillus CST-IV. BAs are 
unique molecules that carry one or more amine groups (NH2). They are essential to mammalian and bacterial 
physiology, tightly controlled in cellular metabolisms. Cadaverine, putrescine, agmatine and tryptamine have 
roles in the metabolism of essential amino acids, including tryptophan and lysine. Their accumulation indi-
cates upheaval or alterations in these metabolic systems. In particular, the odors of the amines cadaverine and 
putrescine are foul-smelling to humans, identifiable as indicators of tissue decomposition associated with death 
or bacterial contamination64,65. Several of these BAs, including cadaverine and putrescine, have previously been 
correlated with diagnosis of BV45,66,67 and implicated in the associated ‘fishy’ vaginal malodor of BV46,47.
Our group recently suggested a hypothetical model for the displacement of vaginal Lactobacillus spp. and 
increased risk of BV and urogenital infection with BAs68. We hypothesize that in the vaginal canal, BAs may 
favor non-Lactobacillus species, while also increasing the vaginal pH, collectively enabling colonization by a 
more diverse community, as is observed with CST-IV. Our hypothesis is based on two observations. First, the 
amino-acid decarboxylation reactions that produce BAs involve the consumption of intracellular hydrogen ions 
and is a well-described bacterial acid resistance and mitigation mechanism52. The consumption of hydrogen 
ions increases the pH of the local habitat52, overcoming what is widely considered the primary barrier to patho-
gen outgrowth and a clinically-recognized symptom of BV. Second, the growth of several pathogens, including 
the urogenital pathogen, Neisseria gonorrhoeae, and their resistance to host immunological defenses has been 
shown to be superior in the presence of various BAs53–55,69. In this study, we observed that lactate was lower 
and BAs were higher, in low-Lactobacillus CST-IV participants as expected. However, lactate was higher in 
Lactobacillus-dominated CST-I/III even when BA concentrations were low. Lactate concentration includes both 
protonated lactic acid (LAH) and lactate anion (LA−) with the former being recognized as the active microbicidal 
form capable of inactivating BV-associated bacteria31,70. Lactate concentrations increase with increasing hydrogen 
ion concentrations31 and therefore the reduction in lactate and increase in BAs further supports our hypotheses, 
and suggest that bacteria present in low-Lactobacillus CST-IV use available hydrogen ions to perform amino acid 
decarboxylation and produce BAs, thus resisting acid stress56.
Figure 4. Metabolites differ between CST. Heatmap displays selection of metabolites with a high fold change 
identified as significantly (q-value = <0.05) different in the vagina of bacterial community state type (CST) 
when unadjusted and adjusted for the impact of smoking status. Low-Lactobacillus CST-IV and Lactobacillus-
dominated CST-I and CST-III are grouped. Quantile regression was conducted on centered and scaled 
metabolite concentrations. Significance testing was conducted with Wilcoxon rank sum test and corrected for 
multiple comparisons.
www.nature.com/scientificreports/
8SCIENTIfIC RePoRTS |  (2018) 8:852  | DOI:10.1038/s41598-017-14943-3
Our results identifying the presence of nicotine breakdown products in smokers may reflect differences in the 
degree of transport and/or accumulation of nicotine and its derivatives in the vagina by CST. These differences 
may relate to the co-variation in pH with CST33. Absorption of nicotine across biological membranes (such as 
cervicovaginal endothelial/epithelial cells) has previously been shown to be pH dependent56,71. Nicotine is a weak 
base (pKa = 8.0) and in acidic environments nicotine does not rapidly cross membranes68. Cotinine and hydrox-
ycotinine are more acidic with a pKa = 4.8 and 4.3, respectively72. Previous studies which have measured both 
in serum and vaginal samples identified higher levels of nicotine in the cervical mucus compared with serum 
samples, yet cotinine values were similar27,63. Nicotine may be selectively concentrated in the vagina because the 
majority (72%) of women display a vaginal pH of 4.0 to 4.633. Conversely, women with low-Lactobacillus CST-IV 
vaginal microbiota have a vaginal pH of 5.3 ± 0.633 and, consistently displayed comparatively lower levels of nic-
otine. Alternatively, these findings may indicate microbiological metabolism of nicotine in the more diverse and 
low-Lactobacillus state of CST-IV.
Similarly, hippurate, a normal excretory product of urine that is increased with exposure to phenolic com-
pounds and toluene, a byproduct of cigarette smoke73, was increased in Lactobacillus-dominated CST-I/III over 
CST-IV and also in non-smokers over smokers. Hippurate is a known substrate of Gardnerella vaginalis74, an 
organism often found in higher abundances when Lactobacillus spp. are low and commonly associated with 
symptomatic BV75–77. Hippurate is decreased in the low-Lactobacillus CST-IV and this may suggest that microbial 
utilization of hippurate and therefore smoking may move the vaginal environment closer to favor the prolifera-
tion of G. vaginalis.
Beyond metabolites directly affiliated with nicotine metabolism, we observed substantive shifts in dipeptides 
and biogenic amines. More than 150 dipeptides in smokers or CST-IV participants were significantly decreased 
relative to non-smokers and those with Lactobacillus spp.-dominated vaginal microbiota. In a previous study, 
Ghartey and colleagues noted significant reductions in vaginal dipeptides among women who delivered infants 
preterm, for which CST-IV and BV are important risk factors78. Dipeptides refer to one or more amino acid 
joined by a peptide bond with important roles in protein metabolism and cell signaling. CST-I and III women had 
higher concentrations of dipeptides relative to CST-IV, suggesting Lactobacillus spp. dominance may be impor-
tant to this phenotype. Dipeptides are constituents of the peptidoglycan cell wall of bacteria and are made during 
its’ synthesis. Therefore, some dipeptides, such as muramyl dipeptides, serve as signal to the immune system 
in mammals and play a direct role in the regulation of inflammation79. Their production has also been indi-
cated in Lactobacillus spp. and other bacteria as a mean of quorum sensing and cellular signaling80. Lactobacillus 
spp. may exploit dipeptides to increase their osmotolerance81, or produce dipeptides for amensalistic purposes. 
Various Lactobacillus spp. have been noted to produce cyclic dipeptides with anti-fungal80,82–84, anti-viral85 and 
anti-bacterial80,86 properties. This includes the production of dipeptides by a vaginal isolate of L. reuteri that 
disrupts the virulence capabilities of Staphylococcus aureus involved in toxic shock syndrome67. The increase 
in dipeptides in non-smokers and Lactobacillus spp.-dominant CSTs may be reflective of increased production 
by Lactobacillus spp. of these bioactive compounds. Conversely, the reduction in dipeptides in women with a 
low-Lactobacillus CST-IV vaginal microbiota may be a result of the increased proteolytic activity from bacteria 
present in this CST. Many BV-associated bacteria have been correlated with, or shown to be capable of secreting 
proteases, which break down proteins into amino acids87–91. Aside from reducing the number of detected dipep-
tides in the vaginal tract, proteases may also have the effect of inactivating proteins important to host defenses and 
make host tissues more susceptible to other organsims’ virulence factors87.
The breakdown compounds of a number of drugs, such as cocaine (norbenzoylecgonine, benzoylecogonine), 
antidepressants (escitalopram), common painkillers (acetaminophen glucoronide, ibuprofen) and decongestants 
(pseudoephedrine) were each observed in one or more samples in the study. This indicates that some drugs could 
possibly be assessed from vaginal metabolomic profiles. There is relatively little known about the relationship 
between individual drugs and their impact on the vaginal microbiome. Cocaine use has been associated with 
shifts in bacterial phyla in the gut92 and additionally has been associated with a greater likelihood of contracting 
sexually transmitted infections93,94. The use of antidepressants has been linked to menstrual disorders and hor-
monal changes in women95,96 both of which may cause indirect shifts in the vaginal microbiota. As these studies 
may suggest a potential impact of drugs and medications and their byproducts on the vaginal microbiota, further 
exploration is needed to make any conclusions.
Our data are consistent with recent studies of the vaginal metabolome45,47,97. In prior studies, the BAs (cadav-
erine, putrescine and tyramine) were consistently higher in women with BV45,47,48,97. We did not detect trimeth-
lyamine in our samples as has previously been identified and we suspect this is due to its high volatility45,47,48,97. 
Srinivasan et al. reported the same issue with their lack of trimethylamine detection using similar methods yet 
reported lower levels of trimethylamine oxide (an intermediary product) in women with BV using separate meth-
ods97. Therefore, there are limitations to the use of metabolomics, including particle resolution, compound sen-
sitivity, polarity and volatility98. Identification of detected metabolites is further constrained by comparison to 
facility-built databases98,99. However, this is best achieved by utilizing standardized collection, preparation and98 
pairing liquid chromatography (LC), gas chromatography (GC) and mass spectrometry (MS) which can enhance 
identification of analytes with differing characteristics98.
Aside from biogenic amines, McMillian et al. reported alpha-hydroxyisovalerate and gamma-hydroxybutyrate 
(GHB) as associated with BV and high bacterial diversity47. We also observed higher levels of alpha-hydroxyisovalerate 
and GHB in low-Lactobacillus CST-IV and additionally we observed a trend towards increases in smokers. 
Alpha-hydroxyisovalerate was positively correlated with diverse BV-associated bacteria such as Atopobium, G. vag-
inalis, Dialister and Gemella. McMillian et al. went on to show how G. vaginalis, a vaginal bacterial species com-
monly associated with BV is a producer of GHB47. Srinivasan et al. also identified 12-hydroxyeicosatetraenoic acid 
(12-HETE) in cases of BV and we also detected a significantly high abundance of this compound in women from 
CST-IV over the Lactobacillus-dominant CSTs (I or III), although it was not associated with smoking status97.
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A limitation of our study was the small sample size and the distribution of smokers and non-smokers within 
each community state type (17 CST-I, 7 CST-III, 12 CST-IV participants). As a result, we have relatively reduced 
power in some of these statistical tests in stratified analyses. Some of the assumptions of traditional parametric 
statistical tests are sensitive to small sample sizes, and the use of non-parametric statistical tests, as was employed 
here, can overcome these assumptions with increased robustness to skewness and outliers. The use of a false 
discovery rate provided a further method for conservative interpretation of these results. We combined L. 
crispatus-dominated CST-I and L. iners-dominated CST-III because in this study, succinate was the only metabo-
lite with abundance significantly different between samples belonging to CST-I compared to CST-III. Combining 
the two CSTs allowed us to increase our statistical power by comparing CST-I/III to CST-IV, however combining 
the L. crispatus and L.iners-dominated communities may not be functionally optimal. There is a growing body 
of research focused on L. iners32,100–103 that aims to evaluate its protective value as part of the vaginal microbiota. 
L. iners is commonly detected in healthy women, and interestingly in women with BV, as well as being among 
the first Lactobacillus spp. to recover after antibiotic treatment for BV104. Further, it is often considered to be a 
tipping point for some women at risk for BV104. Despite the small sample size, this study is unique in its use of 
metabolomics and microbial abundance data in combination with extensive participant behavioral data and its 
rigorous evaluation of smoking status by using quantification of carbon monoxide exhaled and cotinine in saliva. 
The depth of the analyses performed in this study, and the results obtained, may inform where to focus resources 
in a larger confirmatory study.
Conclusions
It is well-documented that a vaginal microbiota dominated by Lactobacillus spp. is associated with reduced risk 
for urogenital infections, including sexually transmitted infections (STIs) and urinary tract (UTIs) infections105. 
In this study, we determined that overall smoking did not affect the vaginal metabolome after controlling for CST, 
but several key metabolites were elevated in smokers. Among women who were smokers and depauperate for 
Lactobacillus spp. (classified as CST-IV), we observed that they had significantly more perturbed metabolic profile 
than other CSTs when compared to their non-smoking counterparts. Biogenic amines were elevated in smokers 
and these metabolites have known roles in anaerobic bacterial proliferation, immune- and stress-resistance with 
a significant link to the development of BV, and possibly other reproductive tract infections. Women who smoke 
may have increased susceptibility to reproductive tract infections due to the observed increase in concentrations 
of BAs and the finding was even more pronounced among women who had low levels of Lactobacillus spp.
The metabolite profile of the vagina was strongly influenced by the resident microbiota as well as cigarette 
smoking in epidemiologic analyses that controlled for possible confounders. Detection of nicotine and its break-
down products in the vagina may serve as molecular biomarkers of smoking. Our results suggest that smoking 
is associated with several important metabolites present in the vagina that may have implications for women’s 
health. This study serves as a pilot for the development of future studies of the mechanisms linking smoking to 
poor gynecologic and reproductive health outcomes.
Methods
Sample Collection. Forty women self-collected mid-vaginal swabs during a single visit at the Center for Health 
Behavior Research at the University of Maryland School of Public Health (UMSPH). The study has previously been 
described30. In brief, smoking burden was determined by saliva cotinine testing, carbon monoxide exhalation levels 
and self-report of smoking habits on a set of comprehensive behavioral surveys. Participants were excluded if they had 
used an antibiotic or antimycotic in the 30 days prior. Four women were excluded from this analysis due to poor DNA 
quality affecting the normalization of the vaginal metabolome dataset (final sample size for analysis was 36 (17 smokers 
and 19 non-smokers) (Table 2). All participants provided written informed consent, and ethical approval was obtained 
from the Institutional Review Boards of the University of Maryland Baltimore (UMB), Montana State University and 
the UMSPH. All samples were collected and analysed in accordance with the relevant guidelines and regulations.
Sample Preparation for Metabolomics. Vaginal samples were eluted from swabs (Starplex rayon swab) 
in 200 µl phosphate buffered saline (PBS) and subjected to both gas chromatography mass spectrometry (GC-MS) 
and liquid chromatography mass spectrometry (LC-MS) with Orbitrap Elite accurate mass platforms (Thermo 
Scientific, Waltham, MA, USA). Sample processing and analysis was performed by Metabolon (Durham, NC, 
USA) using an automated MicroLab STAR® system (Hamilton Company, Reno, NV, USA). Recovery standards 
were added prior to the first step in the extraction process for quality control purposes. Sample preparation was 
conducted using a proprietary series of organic and aqueous extractions to remove the protein fraction while 
allowing maximum recovery of small molecules. The resulting extract was divided into two fractions: one for 
analysis by LC and one for analysis by GC. Samples were placed briefly on a TurboVap® (Zymark, Hopkinton, 
MA, USA) to remove the organic solvent. Each sample was then frozen and dried under vacuum. Samples were 
then prepared for the appropriate instrument, either LC-MS or GC-MS.
Liquid Chromatography and Gas Chromatography Mass Spectrometry. LC-MS measurements 
were conducted on a Waters ACQUITY ultra-performance liquid chromatograph (UPLC) and a ThermoFisher 
Scientific Orbitrap Elite high resolution/accurate mass spectrometer (Thermo Scientific, Waltham, MA, USA), 
which consisted of a heated electrospray ionization (HESI) source and orbitrap mass analyzer operated at a res-
olution 30,000 mass. The sample extract was dried then reconstituted in LC-compatible solvents, each of which 
contained eight or more injection standards at fixed concentrations to ensure injection and chromatographic 
consistency. One aliquot was analyzed using acidic positive ion optimized conditions and the other using basic 
negative ion optimized conditions in two independent injections using separate dedicated columns. Extracts 
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reconstituted in acidic conditions were gradient eluted using water and methanol containing 0.1% formic acid, 
while the basic extracts, which also used water/methanol, contained 6.5 mM ammonium bicarbonate. The MS 
analysis alternated between MS and data-dependent MS2 scans using dynamic exclusion.
Samples for GC-MS analysis were re-dried under vacuum desiccation for a minimum of 24 hours prior to being 
derivatized under dried nitrogen using bistrimethyl-silyl-triflouroacetamide (BSTFA). The GC column was 5% phe-
nyl and the temperature ramp is from 40° to 300 °C in a 16 min period. Samples were analyzed on a Thermo-Finnigan 
Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact ionization. The instrument 
was tuned and calibrated for mass resolution and mass accuracy prior to use. Peaks in the GC-MS and LC-MS data 
were identified using Metabolon’s proprietary peak integration software to resolve sample metabolite peaks over 
noise. Complete details of methods describing metabolomic profiling are described in Lawton et al. (2008)106.
Compound Identification and Preparation. Spectra corresponding to each metabolite were identified by 
comparison to library entries of purified metabolite standards and their distinction from more than 1,000 other com-
mercially available purified standard compounds. The combination of chromatographic properties and mass spectra 
gave an indication of a match to the specific biogenic amine compound or an isobaric entity. Results were manually 
curated to ensure that data were accurate and to remove any system artifacts, miss assignments, and background noise.
Taxonomic Assignment and Community State Type Profiling. DNA extraction, PCR amplification 
and sequencing of 16S rRNA gene amplicons from the vaginal tract of study participants were conducted in a 
prior study30. Briefly, the V1-V3 region of the 16S rRNA gene was PCR amplified using the primers 27F-YM + 3107 
and 534R57 and pyrosequenced using a Roche 454 FLX instrument. Species level assignments of Lactobacillus 
were performed using higher order Markov Chain models using the software speciateIT (speciateIT.sourceforge.
net)33. For each sample, community state types (CSTs) were assigned to individual samples based on diversity 
and relative abundances of different phylotypes as defined in the work of Gajer and Brotman et al.108. The vagi-
nal microbiota samples were categorized into CST-I (L. crispatus-dominated), CST-III (L. iners-dominated) and 
CST-IV (low-Lactobacillus/high strict and facultative anaerobes) (Table 2) Two other well-documented CSTs, 
CST-II (L. gasseri-dominated) and CST-V (L. jensenii-dominated) were not identified in this limited sample and 
are less commonly found even in larger surveys of women33.
Data Analyses. The metabolomic dataset was normalized to DNA concentration and missing values were 
imputed with the minimum detected value for that compound which essentially assigns values based on the sen-
sitivity limit109. Data were then centered and scaled and the median was set equal to 1 prior to log transformation. 
Samples were visualized using a principal components analysis (PCA) (Figure S1). We performed quantile regres-
sion to estimate the median metabolite concentration differences 1) between smokers and non-smokers, 2) between 
CSTs and, 3) also with adjustment for confounding factors. P-values were obtained using the Wilcoxon rank-sum 
test. To correct for multiple tests, false discovery rate (FDR) and q-values were calculated for each compound where 
p = <0.05. Where a p-value estimates the proportion of all tests which will result in false positives (i.e. 5% where 
p-value = 0.05), a q-value estimates the proportion of significant tests that will result in false positives110. Initial 
investigations between Lactobacillus-dominated CST-I and CST-III yielded only one significant difference in the 
metabolite succinate (q-value = 0.009) with adjustment for smoking status. This metabolite was not identified as dif-
fering significantly (q-value = 0.05) in all further analyses, and therefore we grouped CST-I and CST-III for further 
binary analyses to increase power in comparisons to CST-IV. Fold change (FC) was calculated based on Guo et al.111 
where FCi = xi - yi where i is metabolite of interest for the mean value of the control (x) and treatment (y).
We performed distance based linear modeling (DISTLM) by partitioning the distances of compounds using 
distance-based redundancy analysis (dbRDA)112, a form of multivariate multiple regression that can be performed 
directly on a distance or dissimilarity matrix. As the number of participants limits the number of variables that 
can be included in the model, we planned to include just two variables, in addition to our main factors of CST and 
smoking status. Initially we ran individual variables against the metabolite data and selected only those variables 
that were significant (p < = 0.05). These were age, race, marital status, education level, thong undergarment in the 
prior 24 hours, and vaginal douching in the two months prior. The dissimilarity matrix of vaginal metabolites was 
fitted with four of the variables listed in Table 2 and the final model was selected with the greatest adjusted R2 value.
Boxplots and heatmaps were constructed using the ggplot2113 and RColorBrewer (colorbrewer2.org) pack-
ages conducted in R version 3.1.2114. PCA, correlation coefficients, DISTLM and dbRDA plots were produced in 
Primer version 6115.
Data availability. The questionnaire and metabolome data are available at the National Center for 
Biotechnology Information (NCBI) Database of Genotypes and Phenotypes (dbGaP) under Accession number 
phs001386.v1.p1. Metagenomic sequence data were submitted to the public NCBI Sequence Read Archive (SRA) 
with the accession number PRJNA391039.
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